Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$0.93 USD
-0.02 (-1.61%)
Updated Apr 26, 2024 03:59 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXDX 0.93 -0.02(-1.61%)
Will AXDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AXDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXDX
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
AXDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
Other News for AXDX
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (STAA), DarioHealth (DRIO) and Accelerate Diagnostics (AXDX)
Accelerate Diagnostics price target lowered by $1 at Craig-Hallum, here's why
Stockholders Beware: Accelerate Diagnostics’ Surge in Authorized Shares Signals Potential Dilution Risk
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023